Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217509 | 0.85 | EPHX2 (0.35) | LMNAEPHX2TRPV1 | |
| SCHEMBL611384 | 0.85 | ALDH1A1 (0.37) | LMNAEPHX2FAAHTRPV1 | |
| SCHEMBL7158875 | 0.81 | EPHX2 (0.38) | LMNAEPHX2FAAHTRPV1 | |
| SCHEMBL9098243 | 0.81 | EPHX2 (0.38) | LMNAEPHX2FAAHTRPV1 | |
| SCHEMBL8031341 | 0.80 | MMP2 (0.36) | LMNAEPHX2TRPV1 | |
| Acetic Acid SCHEMBL8855968 | 0.80 | TERT (0.38) | LMNAEPHX2FAAHCNR2 | |
| SCHEMBL11208336 | 0.79 | EPHX2 (0.37) | LMNAEPHX2 | |
| SCHEMBL8721243 | 0.77 | EPHX2 (0.38) | LMNAEPHX2FAAHTRPV1 | |
| SCHEMBL2007679 | 0.77 | PSMD14 (0.34) | — | |
| SCHEMBL9955184 | 0.77 | PSMD14 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006316-B2 | Organometallic compositions and coating compositions | KING INDUSTRIES, INC. (US) | 2015-04-14 | — | — | US | claimed |
| US-20120070569-A1 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | KING INDUSTRIES, INC. (US) | 2012-03-22 | — | — | US | claimed |
| US-20090011124-A1 | Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(1-methylimidazole)2(2-ethylhexanoate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes | HSIEH BING | 2009-01-08 | — | — | US | claimed |
| EP-1778778-A2 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | King Industries, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060247341-A1 | Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(tetramethylguanidine)2(formate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes | KING INDUSTRIES, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006022899-A2 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | KING INDUSTRIES, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060036007-A1 | Organometallic compositions and coating compositions | KING INDUSTRIES, INC. (US) | 2006-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070569-A1 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | UROD, AOC1, AOC2 | DEGS1 2447/4885LMNA 4431/4885EPHX2 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.